The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
UBS maintains buy rating for Novartis with price target of 111 francs
UBS has reaffirmed its Buy rating for Novartis, setting a price target of 111 francs, following insights from a recent conference. CFO Harry Kirsch expressed optimism about growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
ubs maintains buy rating for novartis with target of 111 francs
UBS has maintained its 'Buy' rating for Novartis, setting a price target of 111 francs. CFO Harry Kirsch expressed optimism about the company's growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.
UBS maintains buy rating for Novartis with price target of 111 francs
UBS has maintained its "Buy" rating for Novartis, setting a price target of 111 francs, following insights from a recent conference. CFO Harry Kirsch expressed optimism about growth prospects for 2025, coinciding with the expiration of the Entresto patent, according to analyst Matthew Weston.